Redeye initiates coverage of Safello, a Swedish cryptocurrency brokerage founded in 2013 that has ce...
Today (16 December), Elanders announced that it has implemented structural measures regarding its ro...
Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a po...
Surprising Q4 PW and CEO resignation, but likely two isolated events Volatile systems business behin...
Redeye comments on Lipigon's change of CEOs.
Addlife ökade omsättningen med 1% (3% organiskt) till 2 344 MSEK under tredje kvartalet, jämfört med...
Pharma Equity Group (“PEG” or “the Company”) announced on Friday, December the 13th, the board of di...
Redeye leaves a short comment on Stille following the company's announcement that the CEO will resig...
Redeye leaves a comment following Magle’s recent announcement of a directed share issue of approxima...
Verve Group is emerging as a strong adtech player, with particular strength in mobile and growing po...
Redeye comments on the positive news that Emcitate has received a positive CHMP opinion for MCT8 def...
Biovica records another quarter of modest quarterly IVD test sales growth of 50-55% (compared with t...
Redeye comments on the recently announced USD155m fundraising by Ayar Labs, a key partner of Sivers ...
Redeye comments on today’s news, where Nitro Games continues to demonstrate its strategy of being a ...
Redeye was not surprised to see that Powercell last night carried out a directed share issue of SEK1...
Biovica records IVD test sales in Q2 of SEK 0.97m , which is 54% above the previous quarter (Q1) and...
The company downgraded its full year 2024 net sales guidance midpoint by 4% and EBIT guidance midpoi...
Redeye updates its estimates for 2025 after the partnership announcement with the South Korean free-...
Aspo downgraded guidance as ESL’s demand hasn’t picked up as fast as might have been expected earlie...
Redeye comments on the press release from Moberg Pharma last night.